The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group

  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia Group
  4. Cochrane Back Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Consumers and Communication Group
  10. Cochrane Cystic Fibrosis and Genetic Disorders Group
  11. Cochrane Dementia and Cognitive Improvement Group
  12. Cochrane Depression, Anxiety and Neurosis Group
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Ear, Nose and Throat Disorders Group
  16. Cochrane Effective Practice and Organisation of Care Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological Cancer Group
  21. Cochrane Haematological Malignancies Group
  22. Cochrane Heart Group
  23. Cochrane Hepato-Biliary Group
  24. Cochrane HIV/AIDS Group
  25. Cochrane Hypertension Group
  26. Cochrane Incontinence Group
  27. Cochrane Infectious Diseases Group
  28. Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group
  29. Cochrane Injuries Group
  30. Cochrane Lung Cancer Group
  31. Cochrane Menstrual Disorders and Subfertility Group
  32. Cochrane Metabolic and Endocrine Disorders Group
  33. Cochrane Methodology Review Group
  34. Cochrane Movement Disorders Group
  35. Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  36. Cochrane Musculoskeletal Group
  37. Cochrane Neonatal Group
  38. Cochrane Neuromuscular Disease Group
  39. Cochrane Occupational Safety and Health Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Peripheral Vascular Diseases Group
  43. Cochrane Pregnancy and Childbirth Group
  44. Cochrane Prostatic Diseases and Urologic Cancers Group
    1. About this group
    2. Reviews
      1. 5-alpha-reductase inhibitors for prostate cancer preventionReview
      2. Adjuvant chemotherapy for invasive bladder cancer (individual patient data)Review
      3. Adjuvant radiotherapy following radical prostatectomy for prostate cancerReview
      4. Allopurinol for chronic prostatitisReview
      5. Antibiotic prophylaxis for transrectal prostate biopsyReview
      6. Antimicrobial therapy for chronic bacterial prostatitisReview
      7. Beta-sitosterols for benign prostatic hyperplasiaReview
      8. Bisphosphonates for advanced prostate cancerReview
      9. Cernilton for benign prostatic hyperplasiaReview
      10. Chemotherapy for hormone-refractory prostate cancerReview
      11. Cryotherapy for localised prostate cancerReview
      12. Early versus deferred androgen suppression in the treatment of advanced prostatic cancerReview
      13. Finasteride for benign prostatic hyperplasiaReview
      14. Gemcitabine for unresectable, locally advanced or metastatic bladder cancerReview
      15. Immunotherapy for advanced renal cell cancerReview
      16. Intermittent versus continuous androgen suppression for prostatic cancerReview
      17. Interventions for chronic abacterial prostatitisReview
      18. Intravesical Bacillus Calmette-Guérin in Ta and T1 bladder cancerReview
      19. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancerReview
      20. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancerReview
      21. Intravesical gemcitabine for non-muscle invasive bladder cancerReview
      22. Laser prostatectomy for benign prostatic obstructionReview
      23. Low-dose rate brachytherapy for men with localized prostate cancerReview
      24. Lycopene for the prevention of prostate cancerReview
      25. Maximal androgen blockade for advanced prostate cancerReview
      26. Microwave thermotherapy for benign prostatic hyperplasiaReview
      27. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasiaReview
      28. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancerReview
      29. Neo-adjuvant chemotherapy for invasive bladder cancerReview
      30. Neoadjuvant cisplatin for advanced bladder cancerReviewWithdrawn
      31. Non-steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancerReview
      32. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapyReview
      33. Pregabalin for chronic prostatitisReview
      34. Psychosocial interventions for erectile dysfunctionReview
      35. Psychosocial interventions for men with prostate cancerReview
      36. Psychosocial interventions for premature ejaculationReview
      37. Pygeum africanum for benign prostatic hyperplasiaReview
      38. Radical prostatectomy versus watchful waiting for prostate cancerReview
      39. Screening for prostate cancerReview
      40. Screening for testicular cancerReview
      41. Serenoa repens for benign prostatic hyperplasiaReview
      42. Surgery versus radiotherapy for muscle invasive bladder cancerReview
      43. Surgical management for upper urinary tract transitional cell carcinomaReview
      44. Surgical management of localised renal cell carcinomaReview
      45. Tamsulosin for benign prostatic hyperplasiaReview
      46. Targeted therapy for advanced renal cell carcinomaReview
      47. Terazosin for benign prostatic hyperplasiaReview
    3. Protocols
      1. Altered radiation fractionation schedules for clinically localised and locally advanced prostate cancerProtocolNew
      2. Apomorphine for the treatment of erectile dysfunctionProtocol
      3. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstructionProtocol
      4. Exercise interventions for men with prostate cancerProtocol
      5. Laparoscopic versus open prostatectomy for the treatment of localised prostate cancerProtocol
      6. Perioperative nutrition for the treatment of bladder cancer by radical cystectomyProtocol
      7. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasiaProtocol
  45. Cochrane Public Health Group
  46. Cochrane Renal Group
  47. Cochrane Schizophrenia Group
  48. Cochrane Sexually Transmitted Infections Group
  49. Cochrane Skin Group
  50. Cochrane Stroke Group
  51. Cochrane Tobacco Addiction Group
  52. Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
  53. Cochrane Wounds Group